Frazer, PA, United States of America

Mark A Collins

This inventor holds 1 USPTO granted patent. Top assignee: Bearsden Bio, Inc.. Active years: 2000.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mark A Collins. Retrieved from https://idiyas.com/inventor/mark-a-collins-z9k6forj

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2000

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovator Spotlight: Mark A Collins

Introduction: Mark A Collins is a notable inventor based in Frazer, Pennsylvania, recognized for his contributions to the field of biochemistry. With a dedicated focus on innovations that impact excitatory amino acid receptors, his inventive process has led to significant advancements within the scientific community.

Latest Patents: Collins holds a patent for "1-arylphthalazine antagonists of excitatory amino acid receptors." This innovative composition comprises substituted 1-arylphthalazine formulations, showcasing his commitment to exploring new therapeutic avenues in neuropharmacology.

Career Highlights: Collins is closely affiliated with Bearsden Bio, Inc., where he applies his expertise to drive research and development forward. His work is characterized by an in-depth understanding of molecular interactions and mechanisms influencing neurotransmitter activity.

Collaborations: Collins collaborates closely with Jeffrey Claude Pelletier, leveraging their combined knowledge to enhance research outcomes. Their partnership exemplifies the spirit of teamwork essential in the innovation landscape, fostering an environment where ideas can flourish.

Conclusion: Through his patent and ongoing research, Mark A Collins is making significant strides in the field of pharmacology. His contributions not only advance scientific knowledge but also pave the way for potential therapeutic applications that could benefit many.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…